Web Desc
Advances in Cancer Immunotherapy - VIRTUAL CONTENT AVAILABLE ON DEMAND
Organizer(s): Antoni Ribas and Priti Hegde
Date: August 17 - 19, 2020
Location: Virtual at your computer. Recorded presentation content is available On Demand.
Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation
For important information on the coronavirus, please click here
Summary of Meeting:
Cancer immunotherapy by blocking immune inhibitory checkpoints or engineering T cells for adoptive cell transfer is providing an unprecedented level of long-term antitumor activity in patients with several metastatic cancers. However, the majority of patients with advanced cancers still do not experience sustained clinical benefit from immunotherapy. Understanding the mechanistic basis of response and resistance to these therapies and how therapeutic approaches could best be combined will be essential to continue progress. The largest human experiment is currently being conducted with over 1,000 agents and combinations. Understanding the results to date and determining what is working and what combinations are not working will be important to refine our understanding of immunity in patients with cancer. Questions that remain unanswered include: What is the rationale for the multiple immuno-oncology (IO) combinations being tested in the clinic, how do cancers adapt and resist T cell attack, and can we better understand the tumor microenvironment, thus paving the way for new approaches to cancer therapy. New analyses of patient-derived samples provide information on adaptive and genetic resistance mechanisms to immunotherapy. The conference program will include sessions which cover topics such as new analysis techniques, methodologies, and how to integrate high throughput data to provide a more comprehensive understanding of cancer and the immune system. Participants will leave the conference with an understanding of how the advancement of cancer biology will be influenced by a better comprehension of tumor immunology.
Global Health Travel Award Deadline: August 10 2020
Scholarship Deadline: August 19 2020
Abstract Deadline: August 10 2020
We gratefully acknowledge additional support for this conference from:
Agilent (Seahorse)American Association for Cancer Research (AACR)
We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1R13CA246936-01
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Monday, August 17 | 8:00AM - 8:10AM
Introductory Remarks (Organizers)


Monday, August 17 | 8:10AM - 8:40AM
Keynote Address

Speaker 1 of 1
James P. Allison, University of Texas MD Anderson Cancer Center, USA
Immune Checkpoint Blockade in Cancer Therapy: New Insights into Therapeutic Mechanisms

Monday, August 17 | 8:40AM - 9:35AM
Mechanisms of Action I

Speaker 1 of 3
* Ira Mellman, Genentech, Inc., USA
Mechanistic Basis of Cancer Immunotherapy

Monday, August 17 | 8:40AM - 9:35AM
Mechanisms of Action I

Speaker 2 of 3
* Kelli Connolly, Yale University, USA
Short Talk: Tumor-Draining Lymph Nodes Contain an Untapped Reservoir of Stem-Like CD8 T Cells

Monday, August 17 | 8:40AM - 9:35AM
Mechanisms of Action I

Speaker 3 of 3
AHyun Choi, Novartis Institutes for BioMedical Research, USA
Short Talk: Loss of EMC Inhibits Tumor Growth through Enhanced Adaptive Immune Response

Monday, August 17 | 9:35AM - 10:00AM
Break


Monday, August 17 | 10:00AM - 11:05AM
Mechanisms of Action II

Speaker 1 of 4
Jane Oliaro, Peter MacCallum Cancer Centre, Australia
Identifying New Targets for Cancer Immunotherapy

Monday, August 17 | 10:00AM - 11:05AM
Mechanisms of Action II

Speaker 2 of 4
Vandana Kalia, University of Washington and Seattle Children’s Research Institute, USA
Short Talk: PD-1 Signals Are Critical for Maintenance of CD8 T Cell Memory

Monday, August 17 | 10:00AM - 11:05AM
Mechanisms of Action II

Speaker 3 of 4
Katie Campbell, University of California, Los Angeles, USA
Short Talk: Integrating DNA and RNA Sequencing Analysis to Describe Somatic Alterations and Expression in the HLA Gene Loci

Monday, August 17 | 10:00AM - 11:05AM
Mechanisms of Action II

Speaker 4 of 4
Stephen Mok, MD Anderson Cancer Center, USA
Short Talk: Late Interferon-Gamma Blockade Improves Antitumor Efficacy of Anti-CTLA-4 and Anti-PD-1 Combination Treatment

Monday, August 17 | 11:05AM - 3:00PM
Break


Monday, August 17 | 12:00PM - 1:00PM
Career Roundtable

Speaker 1 of 3
Yvonne Y. Chen, University of California, Los Angeles, USA

Monday, August 17 | 12:00PM - 1:00PM
Career Roundtable

Speaker 2 of 3
Priti Hegde, Foundation Medicine, USA

Monday, August 17 | 12:00PM - 1:00PM
Career Roundtable

Speaker 3 of 3
Evan Scott, Northwestern University, USA

Monday, August 17 | 3:00PM - 3:05PM
Introductory Remarks


Monday, August 17 | 3:05PM - 4:25PM
Mechanisms of Response I

Speaker 1 of 3
* Siwen Hu-Lieskovan, Huntsman Cancer Institute, USA
Clinical Testing Strategies against Heterogenous Mechanisms of Immune Resistance

Monday, August 17 | 3:05PM - 4:25PM
Mechanisms of Response I

Speaker 2 of 3
Antoni Ribas, University of California, Los Angeles, USA
Mechanisms of Primary and Acquired Resistance to PD-1 Blockade Therapy

Monday, August 17 | 3:05PM - 4:25PM
Mechanisms of Response I

Speaker 3 of 3
Chang Liu, University of Pittsburgh, USA
Short Talk: Neuropilin-1 Is a T Cell Memory Checkpoint Limiting Long-Term Anti-Tumor Immunity

Monday, August 17 | 4:25PM - 4:50PM
Break


Monday, August 17 | 4:50PM - 6:00PM
Mechanisms of Response II

Speaker 1 of 4
Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA
From the Clinic to the Lab: Investigating Mechanisms of Response and Resistance to Immune Checkpoint Therapy

Monday, August 17 | 4:50PM - 6:00PM
Mechanisms of Response II

Speaker 2 of 4
* Yuxuan Miao, Rockefeller University, USA
Short Talk: Adaptive Immune Resistance Emerges From Tumor-Initiating Stem Cells

Monday, August 17 | 4:50PM - 6:00PM
Mechanisms of Response II

Speaker 3 of 4
Shira Tabachnick-Cherny, University of Washington, USA
Short Talk: Characterization of Myeloid Cells Subsets in the Tumor Microenvironment of Merkel Cell Carcinoma

Monday, August 17 | 4:50PM - 6:00PM
Mechanisms of Response II

Speaker 4 of 4
Zoila Areli Lopez Bujanda, Johns Hopkins University, USA
Short Talk: ADT-Mediated Intra-Tumoral Myeloid Infiltration Promotes Resistance to Immune Checkpoint Blockade in Prostate Cancer

Monday, August 17 | 7:30PM - 10:00PM
Poster Session


Tuesday, August 18 | 8:00AM - 8:05AM
Introductory Remarks


Tuesday, August 18 | 8:05AM - 9:40AM
Therapeutic Play I

Speaker 1 of 5
Yvonne Y. Chen, University of California, Los Angeles, USA
Engineering Next-Generation CAR-T Cell Therapy for Cancer

Tuesday, August 18 | 8:05AM - 9:40AM
Therapeutic Play I

Speaker 2 of 5
* Juan C. Jaen, Arcus Biosciences, Inc., USA
Clinical Applications of Adenosine Pathway Inhibitors

Tuesday, August 18 | 8:05AM - 9:40AM
Therapeutic Play I

Speaker 3 of 5
Coralie Backlund, Massachusetts Institute of Technology, USA
Short Talk: Cell Penetrating Peptides Improve T Cell Response to Neoantigen Peptide Vaccines

Tuesday, August 18 | 8:05AM - 9:40AM
Therapeutic Play I

Speaker 4 of 5
Maija Hollmén, University of Turku, Finland
Short Talk: Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumours

Tuesday, August 18 | 8:05AM - 9:40AM
Therapeutic Play I

Speaker 5 of 5
Yingxiao Wang, University of California, San Diego, USA
Short Talk: Engineering Remotely Controllable CAR T Cells for Cancer Immunotherapy

Tuesday, August 18 | 9:40AM - 11:15AM
Therapeutic Play II

Speaker 1 of 5
* Evan Scott, Northwestern University, USA
Engineered Nanobiomaterials for Cancer Immunotherapy

Tuesday, August 18 | 9:40AM - 11:15AM
Therapeutic Play II

Speaker 2 of 5
E. John Wherry, University of Pennsylvania, USA
Epigenetic Features of Exhausted Antitumor T Cells

Tuesday, August 18 | 9:40AM - 11:15AM
Therapeutic Play II

Speaker 3 of 5
Buvana Ravishankar, Rapt Therapeutics, Inc., USA
Short Talk: Targeting the Stress Response Kinase GCN2 Potentiates Anti-Tumor Immune Response

Tuesday, August 18 | 9:40AM - 11:15AM
Therapeutic Play II

Speaker 4 of 5
Anthony K. Park, City of Hope, USA
Short Talk: Effective Combination Immunotherapy using Oncolytic Viruses to Deliver CAR Targets to Solid Tumors

Tuesday, August 18 | 9:40AM - 11:15AM
Therapeutic Play II

Speaker 5 of 5
Patrick A. Ott, Dana-Farber Cancer Institute, USA
Short Talk: Personal Neoantigen Vaccines Induce Long-term Immune Responses in Patients with High Risk Melanoma

Tuesday, August 18 | 11:15AM - 3:00PM
Break


Tuesday, August 18 | 12:00PM - 1:00PM
Meet-the-Editors Roundtable

Speaker 1 of 3
Alessandra Fornarelli, Frontiers, Switzerland

Tuesday, August 18 | 12:00PM - 1:00PM
Meet-the-Editors Roundtable

Speaker 2 of 3
Paloma Portela Torres, SAGE Publications Ltd, UK

Tuesday, August 18 | 12:00PM - 1:00PM
Meet-the-Editors Roundtable

Speaker 3 of 3
Lise Roth, European Molecular Biology Organization, Germany

Tuesday, August 18 | 3:00PM - 3:05PM
Introductory Remarks


Tuesday, August 18 | 3:05PM - 4:25PM
Genomics of Cancer I

Speaker 1 of 4
* Priti Hegde, Foundation Medicine, USA
Pan-Cancer Analysis of Allele-Specific HLA-I Loss Suggests Widespread Occurrence across a Diverse Range of Tumor Types

Tuesday, August 18 | 3:05PM - 4:25PM
Genomics of Cancer I

Speaker 2 of 4
Eliezer M. Van Allen, Dana-Farber Cancer Institute, USA
Tumor Genomics and Selective Response to Cancer Immunotherapy

Tuesday, August 18 | 3:05PM - 4:25PM
Genomics of Cancer I

Speaker 3 of 4
* Nadine A. Defranoux, Parker Institute for Cancer Immunotherapy, USA
Short Talk: Strategies to Improve the Sensitivity and Ranking Ability of Neoantigen Prediction Methods: Report on the Results of the Tumor nEoantigen SeLection Alliance (TESLA)

Tuesday, August 18 | 3:05PM - 4:25PM
Genomics of Cancer I

Speaker 4 of 4
Gloria Bora Kim, University of Pennsylvania, USA
Short Talk: Splice Variants as Neoantigens for Cancer Immunotherapy

Tuesday, August 18 | 4:25PM - 4:50PM
Break


Tuesday, August 18 | 4:50PM - 6:00PM
Genomics of Cancer II

Speaker 1 of 3
Elaine R. Mardis, Nationwide Children's Hospital, USA
Immunogenomics and the TME in Pediatric CNS Cancers

Tuesday, August 18 | 4:50PM - 6:00PM
Genomics of Cancer II

Speaker 2 of 3
Thomas D. Wu, Genentech, Inc., USA
Short Talk: Peripheral T Cell Expansion Predicts Tumor Infiltration and Clinical Response to Cancer Immunotherapy

Tuesday, August 18 | 4:50PM - 6:00PM
Genomics of Cancer II

Speaker 3 of 3
Debattama Sen, Massachusetts General Hospital, USA
Short Talk: Disrupting Enhancers within the Core Epigenetic Program of Exhaustion Improves CD8+ T Cell Responses and Enhances Tumor Control

Wednesday, August 19 | 8:00AM - 8:05AM
Introductory Remarks


Wednesday, August 19 | 8:05AM - 9:25AM
Single Cell I

Speaker 1 of 4
James R. Heath, Institute for Systems Biology, USA
Single Cell Approaches to Analyzing Antitumor Responses

Wednesday, August 19 | 8:05AM - 9:25AM
Single Cell I

Speaker 2 of 4
* Ansuman Satpathy, Stanford University School of Medicine, USA
Single-Cell Genomics in Cancer Immunotherapy

Wednesday, August 19 | 8:05AM - 9:25AM
Single Cell I

Speaker 3 of 4
Christine Carine Moussion, Genentech, Inc., USA
Short Talk: Local Heterogeneity of Response to CIT: Learning from the STAMP Live Imaging Model

Wednesday, August 19 | 8:05AM - 9:25AM
Single Cell I

Speaker 4 of 4
James C. Lee, University of California, San Francisco, USA
Short Talk: Liver Metastasis Mediated Control of Systemic Tumor-Specific Immunity and Response to Checkpoint Immunotherapy

Wednesday, August 19 | 9:25AM - 9:45AM
Break


Wednesday, August 19 | 9:45AM - 10:40AM
Single Cell II

Speaker 1 of 3
* Sohail F. Tavazoie, Rockefeller University, USA
Depleting Myeloid-Suppressive Cells for Cancer Immunotherapy

Wednesday, August 19 | 9:45AM - 10:40AM
Single Cell II

Speaker 2 of 3
Theodore Roth, University of California, San Francisco, USA
Short Talk: Parallel Engineering of Immune Cell Genomes by Pooled Knockin Targeting

Wednesday, August 19 | 9:45AM - 10:40AM
Single Cell II

Speaker 3 of 3
Amanda Oliver, Peter MacCallum Cancer Centre, Australia
Short Talk: Tissue-Specific Tumour Microenvironments Influence Responses to Immunotherapy

Wednesday, August 19 | 10:40AM - 11:00AM
Closing Remarks (Organizers)


*Session Chair.